ArticleJGH open : an open access journal of gastroenterology and hepatology2026
Therapeutic Drug Monitoring of Vedolizumab Levels During Maintenance in Inflammatory Bowel Disease (MOVE-IBD).
Article in JGH open : an open access journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Drug Monitoring of Vedolizumab Levels During Maintenance in Inflammatory Bowel Disease (MOVE-IBD).JGH open : an open access journal of gastroenterology and hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Therapeutic drug monitoring (TDM) of non anti-TNF biologics is not well established in clinical practice. We aimed to clarify the association between VTL and remission in our cohort of maintenance vedolizumab patients using objective markers of disease activity to see if this could aid in decision making. Methods: A retrospective cross-sectional cohort study was performed on 83 consecutive moderate-severe inflammatory bowel disease (IBD) patients. VTL measurement immediately prior to infusion was paired with clinical and objective markers of disease activity. Objective disease assessment was undertaken using fecal calprotectin, magnetic resonance imaging, intestinal ultrasound, or sigmoidoscopy/colonoscopy. Results: Eighty-three patients on maintenance vedolizumab were evaluated (59% UC and 41% CD). The median age at diagnosis was 40 years. Median trough vedolizumab levels were comparable in patients who achieved steroid-free clinical remission (12.65 μg/mL vs. 8.89 μg/mL Conclusion: Vedolizumab trough levels were not associated with clinical or objective remission during maintenance therapy, and in our real-world cohort, do not appear to be a clinically relevant target for TDM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.